

00/90/60

09-07-00

PATENT/Docket No.: 6107.N CN2

jc813 U.S. PTO
09/06/00
09/656364

09/06/00

CERTIFICATE OF MAILING (37 CFR 1.10)

"Express Mail" No.: EL598997811 US

Date of Deposit: September 6, 2000

I hereby certify that this transmittal together with the patent application referred to below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Julie K. Lyons, Legal Assistant

Name of Person Mailing Paper

Julie K Lyons
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner of Patents and Trademarks
Washington, DC 20231

**REQUEST FOR FILING A PATENT APPLICATION
UNDER 37 CFR 1.53(b)**

Sir:

Applicant(s) hereby request the filing of a ☒ continuation ☐ divisional application under 37 CFR 1.53(b), of the pending prior application identified as follows:

Applicant(s) : A. C. Martino, et al.
Serial No. : 09/327135
Filed : June 7, 1999
For : DELAVIRDINE TABLET FORMULATION

Attached is a true copy of the prior complete application as filed including the specification (including claims), drawings, oath or declaration and any amendments referred to in the oath or declaration filed to complete the prior application. No amendments referred to in the oath or declaration filed to complete the prior application introduced new matter therein. The Power of Attorney appears in the Declaration or Oath executed in the prior application as filed and a copy is attached hereto. A new Declaration or Oath is thus not required pursuant to 37 CFR 1.63(d).

The particulars of this request are set forth below:

[X] This paper is being filed under the provisions of 37 CFR 1.10 and contains hereon the required Certificate of Mailing by "Express Mail".

I. AMENDMENTS IN CONNECTION WITH FILING

- A. ☒ Please cancel claims 25, 27-29, 31 and 32 as they appear in the attached application.
- B. ☒ Please enter the preliminary amendment provided herewith.
- C. ☐ New formal drawings are enclosed.

- D. ☒ Please amend the attached application by providing a new cross reference to related applications before the first line of the specification which reads as follows:

The present Patent Application is a continuation of U.S. Patent Application Serial No: 09/327,135, filed June 7, 1999, which claims the benefit of U. S. Provisional Application Serial no: 60/088,960, filed June 11, 1998, under 35 USC § 119(e)(i).

II. FILING FEES

The filing fee has been calculated as shown below for the claims pending after the claims cancelled in Part I.A.:

	Total No. of Claims	No. of Claims Without Additional Fee	Excess Claims	\$ Rate	Fee
Total Claims Fee	27	20	7	x 18	126
Independent Claims Fee	1	3		x 78	0
Multiple Dependent Claim	0			x 260	0
Basic Fee					690
Total Filing Fee					\$ 816

SPECIFIC DEPOSIT ACCOUNT AUTHORIZATION. Please charge my Deposit Account No. 21-0718 in the amount of the total filing fee above. Triplicate copies of this paper are enclosed.

GENERAL DEPOSIT ACCOUNT AUTHORIZATION. The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or during the pendency of this application or credit any overpayment to Deposit Account No. 21-0718:

- (1) Any additional filing fees or fees for the presentation of additional claims required under 37 CFR 1.16.
- (2) Any patent application processing fees under 37 CFR 1.17.

No authorization is given to charge the Issue Fee (37 CFR 1.18).

III. ADDITIONAL INFORMATION

- A. ☐ Priority of foreign application Serial No. _____ filed on _____ in _____ is claimed under 35 USC 119.

The certified copy has been filed in prior application Serial No. _____, filed _____.


- B. ☐ The prior application is assigned of record to:
- C. ☒ The applicant(s) for the present application are the same as those identified in the above-referenced application.

D. ☐ In accordance with 37 CFR 1.53(d)(4), the deletion of the following person or persons from the new application is requested as this person or persons are not inventors of the invention being claimed in the new application:

E. ☐ The current correspondence address of the applicant(s), if different from that set forth in applicant(s) declaration (37 CFR 1.63), is as follows:

The undersigned hereby requests that all correspondence and telephone communications in connection with this application be directed to the undersigned person at the mailing address and telephone number shown below.

Respectfully submitted,



Date: 00-9-6

Bruce Stein, Attorney
Registration No. 27,231

Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (616) 833-1127 or (616) 833-9500
Telefax No. (616) 833-8897 or (616) 833-2316

Attachments:

- ☒ Executed Prior Application as Originally Filed
- ☒ Form 53B (in triplicate)
- ☒ Preliminary Amendment

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1616 (Probably)
Examiner : Shahnam Sharareh
Applicant(s) : A. C. Martino, et al
Serial Number: 09/
Filed : 00-9-
For : TABLET FORMULATION

Assistant Commissioner of Patents
Washington, DC 20231

PRELIMINARY AMENDMENT UNDER 37 C.F.R. §1.121

Sir:

Please amend as follows:

In the title:

Change the title to "TABLET FORMULATION"

In the claims:

In claim 1; page 8, line 8, after "grinding" add – with the proviso that the rapidly precipitation drug is not delavirdine mesylate. –

In all claims, in the first line, between "release" and "pharmaceutical" add – non-chewable --.

Cancel claims 25, 27-29, 31 and 32.

REMARKS

Claims 1-24, 26 and 30 are in the present patent application.

The amendments are made so as not to duplicate what is claimed in US patent application Serial No. 09/327,135 and to clarify that the claimed tablet formulation is NOT a chewable tablet.

Respectfully,

09/327,135

Table 1. Demographic characteristics of the study population	
Age (years)	50.0 ± 10.0
Gender (male/female)	100/100
Education (years)	12.0 ± 2.0
Occupation (white/blue collar)	50/50
Marital status (married/divorced/separated/widowed)	80/20
Family size (number of children)	2.0 ± 1.0
Income (US\$ per month)	1,500 ± 500
Health insurance (yes/no)	90/10
Smoking status (current/former/never)	30/40/30
Alcohol consumption (yes/no)	20/80
Exercise frequency (times per week)	1.0 ± 1.0
Stress level (low/moderate/high)	30/40/30
Comorbidities (hypertension/diabetes/cholesterol)	20/10/10
Medication use (yes/no)	10/90
Healthcare utilization (times per year)	2.0 ± 1.0
Quality of life score (0-100)	60.0 ± 10.0
Overall health status (good/fair/poor)	40/30/30

DELAVIDINE TABLET FORMULATIONBACKGROUND OF THE INVENTION**Cross-Reference to Related Applications**

This application claims the benefit of US provisional application Serial No.
5 60/088,960 filed 11 June 1998, under 35 USC §119(e)(i).

1. Field of the Invention

The present invention is a tablet formulation which reduces the rate of precipitation of a rapidly precipitating drug and improves dissolution.

2. Description of the Related Art

10 US Patent 5,563,142 (EXAMPLE 105) discloses delavirdine.

International Publication WO95/28398 based on PCT patent application PCT/US95/02166 discloses delavirdine mesylate in two crystal forms "S" and "T".

US Patent 5,358,941 discloses a compressed tablet formulation comprising about 0.5 to 40% active ingredient, about 10-80% anhydrous lactose, about 5 to 50%
15 by weight of microcrystalline cellulose, about 0.5 to 10% by weight of croscarmallose sodium and about 0.1 to 5% magnesium stearate. The pharmaceutical tablet formulation of the present invention does not require lactose.

Patent EP 283925 discloses utilization of solvent-based polymers under action of high shearing forces so that precipitation is divided into smallest particles to purify
20 resorbable polyester products. The claimed invention does not co-precipitate polymers in any solvent system with the rapidly precipitating drug prior to formulation with other ingredients, but relies only on close proximity of the dry binder or superdisintegrant with the rapidly precipitating drug in a conventional compressed tablet dosage form.

25 *International Journal of Pharmaceutics*, 154, 59-66 (1997) discloses the utilization of HPMC, HPC and PVP in a liquid system at various polymer ratios with intent to delay precipitation. Methods discussed include preparation of solid dispersions either by the co-precipitation method of grinding method to improve dissolution properties. The claimed invention utilizes conventional direct compression
30 method of tablet formulation and does not utilize any solid dispersion techniques such as co-precipitation via solvent use or grinding to achieve co-precipitation.

The Handbook of Drug Excipients, 2nd. Ed., edited by A. Wade and P. J. Weller. 1994, page 141, and many other pharmaceutical references, describe the common use of superdisintegrants such as croscarmellose sodium are used to aid tablet
35 disintegration typically in the amount of 1-2% and not more than 5% of the formulation. Higher amounts are not used or recommended due to gelation of the

croscarmellose sodium forming a loose matrix which is known to impede dissolution of many drug compounds. The present invention uses greater than 6% croscarmellose sodium.

The Handbook of Drug Excipients, 2nd. Ed., edited by A. Wade and P. J. Weller. 1994, pages 223, 229 and 392, and many other pharmaceutical references, describe the common use of water soluble polymers such as HPMC, HPC-L, and PVP as binders, either as wet binders or dry binders, in immediate and sustained release tablet formulations. For non-sustained release applications, not more than 5% is used of these binders. Higher amounts are not recommended due to impedance of the dissolution rate for many drugs. Amounts higher than 5% of especially HPMC are commonly used only for sustained release dosage forms, and are generally of high molecular weight grades. In the present invention, however, the binder includes use at levels of greater than 5%.

US Patent 5,225,197 discloses a chewable tablet formulation. The present invention is not a chewable tablet.

JP 84-185584 discloses the utilization of HPC, PVP and other binders together with difficulty soluble drugs by use of heat. The claimed invention does not use heat.

SUMMARY OF INVENTION

Disclosed is a non-sustained release pharmaceutical tablet composition which comprises: a rapidly precipitating drug in an amount from about 5 to about 60%, microcrystalline cellulose and at least one member selected from the group consisting of a binder in an amount of from about 2 to about 25% and a superdisintegrant in an amount from about 6 to about 40% where the rapidly precipitating drug, microcrystalline cellulose, binder and superdisintegrant are mixed and compressed into a tablet without heating, solvent or grinding.

Also disclosed is a non-sustained release pharmaceutical tablet composition which is:

		<u>Amount (from about to about)</u>
	<u>Item</u>	<u>%</u>
30	delavirdine mesylate	10-40
	hydroxypropyl methylcellulose	5-20
	croscarmellose sodium	6-35
	microcrystalline cellulose	10-50
	lactose	0-15
35	colloidal silicon dioxide	0-5
	magnesium stearate	0-5

where the delavirdine mesylate, microcrystalline cellulose, hydroxypropyl methylcellulose and croscarmellose sodium are mixed and compressed into a tablet without heating, solvent or grinding.

DETAILED DESCRIPTION OF THE INVENTION

- 5 The tablets of the present invention require a rapidly precipitating drug (5-60%), microcrystalline cellulose (10-50%), a binder (2-25%) and superdisintegrant (6-40%). While not required, it is often highly desirable to use one or more of the following pharmaceutical ingredients - microcrystalline cellulose (0-50%), lactose (0-80), a flow agent (0-5) and a lubricant (0-5%).
- 10 A rapidly precipitating drug is a pharmaceutical compound, or its salt form, which when introduced in water, or simulated physiological fluids at body temperature, begins to dissolve fairly rapidly and then begins to rapidly precipitate out of solution within 60 min to a less soluble form which provides a concentration that is less than therapeutic. This precipitation results in slow and incomplete
- 15 dissolution. In most cases, the amount precipitating can be up to 90% or greater which leave about 10% or less available for therapeutic activity. It is preferred that the rapidly precipitating drug is a fairly soluble or highly soluble salt form of a poorly soluble free base or free acid drug or an anhydrous form of a poorly soluble free base or free acid drug. The rapidly precipitating drugs are prone to supersaturation as is
- 20 known to those skilled in the art. It is preferred that the rapidly precipitating drug be selected from the group consisting of delavirdine mesylate, phenytoin, furosemide, pseudoephedrine, clindamycin hydrochloride, cloridine hydrochloride, diphenhydramine hydrochloride, fluphenazine hydrochloride, griseofulvin, hydromorphone hydrochloride, naloxone hydrochloride, oxytetracycline hydrochloride,
- 25 phenylephrine hydrochloride, pheniramine maleate, tetracycline hydrochloride, verapamil hydrochloride, propoxyphene hydrochloride, propoxyphene napsylate, hydrocodine bitartrate, acyclovir sodium, albuterol sulfate, ampicillin sodium, benztropine mesylate, benzphetamine hydrochloride, bupivacaine hydrochloride, bupropin hydrochloride, chlorphenamine maleate, chlorpromazine hydrochloride. It is
- 30 most preferred that the rapidly precipitating drug is delavirdine mesylate. The rapidly precipitating drug should be present in an amount of about 5 to about 60%, preferably in an amount of about 10 to about 40%.

Delavirdine, 1-[5-methanesulfonamidoindolyl]-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine is known, see US Patent 5,563,142 (EXAMPLE 105).

- 35 Delavirdine mesylate is also known in two different crystal forms "S" and "T", see,

International Publication WO95/28398 based on PCT patent application
PCT/US95/02166.

The tablet formulation of the present invention is a non-sustained release pharmaceutical tablet composition which comprises a rapidly precipitating drug in an amount from about 5 to about 60%, microcrystalline cellulose (10-50%) and at least one member selected from the group consisting of a binder in an amount of from about 2 to about 25% and a superdisintegrant in an amount from about 6 to about 40% where the rapidly precipitating drug, microcrystalline cellulose, binder and superdisintegrant are mixed and compressed into a tablet without heating, solvent or grinding. It is preferred that the binder, microcrystalline cellulose and superdisintegrant all be present.

The tablet formulation of the present invention can use a binder. The binder is preferably selected from the group consisting of hydroxypropyl methylcellulose, PVP, hydroxypropyl cellulose, microcrystalline cellulose, hydroxymethylcellulose, carbopol and sodium carboxymethylcellulose; it is more preferred that the binder be selected from the group consisting of hydroxypropyl methylcellulose and more preferably 2910 U.S.P. 3 cps. Also preferred is PVP. It is preferred that the binder be present in an amount of hydroxypropyl methylcellulose of from about 5 to about 20%, PVP from about 2 to about 15%, hydroxypropyl cellulose or hydroxyethylcellulose from about 5 to about 20%, carbopol, methylcellulose, and sodium carboxymethylcellulose from about 3 to about 20%. It is apparent to those skilled in the art that the binders of the present invention are polymeric binders as opposed to non-polymeric binders.

The superdisintegrant is selected from the group consisting of croscarmellose sodium, sodium starch glycolate, L-hydroxypropyl cellulose; it is more preferred that the superdisintegrant be croscarmellose. The superdisintegrant should be present in an amount of from about 6% to about 40%. It is preferred that the superdisintegrant is present in an amount of from about 6 to about 35%; it is more preferred that the superdisintegrant be present in an amount of about 10 to about 30%. This is one of the agents responsible for delaying the precipitation of the rapidly precipitating drug.

The microcrystalline cellulose is not absolutely necessary to prepare the tablet formulation of the present invention. However, it is highly desirable to have it present in most cases. The tablet formulation can use a microcrystalline cellulose diluent.

When present it is preferred that it can be selected from the group consisting of microcrystalline cellulose coarse powder, microcrystalline cellulose medium powder and microcrystalline cellulose 200; it is more preferred that the microcrystalline

cellulose be microcrystalline cellulose N.F. coarse powder. The microcrystalline cellulose should be present in an amount of from about 5% to about 50%. It is preferred that the microcrystalline cellulose be present in an amount of from about 10 to about 50%.

5 The lactose is not absolutely necessary to prepare the tablet formulation of the present invention. However, it is highly desirable to have it present in most cases in an amount up to about 80%. When present it is preferred that it be selected from the group consisting of lactose monohydrate spray process standard, lactose monohydrate, lactose anhydrous, lactose dihydrate, DMV lactose; it is more preferred that the
10 lactose be N.F. monohydrate spray process standard lactose. The lactose can be present in an amount of from about 0% to about 80%. It is preferred that the lactose be present in an amount of from about 5 to about 20%.

 The flow agent is not absolutely necessary to prepare the tablet formulation of the present invention. However, it is highly desirable to have it present in most
15 cases. When present it is preferred that it be selected from the group consisting of colloidal silicon dioxide and talc; it is more preferable that the flow agent be selected from the group consisting of colloidal silicon dioxide N.F. When present, the flow agent should be present in an amount up to about 5%. It is preferred that the flow agent be present in an amount of from 0.25 to about 2%.

20 The lubricant is not absolutely necessary to prepare the tablet formulation of the present invention. However, it is highly desirable to have it present in most cases. When present, it is preferred that the lubricant is selected from the group consisting of magnesium stearate and stearic acid; it is more preferred that the lubricant be magnesium stearate. When present, the lubricant should be present in
25 an amount up to about 5%. It is preferred that the lubricant be present in an amount of 0.25 to about 2%.

 As is known to those skilled art, the tablet can be colored, flavored and/or film coated as is known to those skilled in the art.

 The tablet composition of the present invention is prepared as is known to
30 those skilled in the art as direct compression. It is preferred to first mix the rapidly precipitating drug with the microcrystalline cellulose very thoroughly by methods well known to those skilled in the art, preferably by use of a high shear mixer. The hydroxypropyl methylcellulose, croscarmellose, lactose, and screened colloidal silicon dioxide are mixed separately, preferably in a high shear mixer, and added to the drug-
35 microcrystalline cellulose mixture and all the ingredients are thoroughly mixed, preferably in a high shear mixer. The magnesium stearate is screened and added to

the drug mixture and mixed well. The resulting mixture is compressed by methods well known to those skilled in the art to produce tablets containing the desired amount of active pharmaceutical agent. These tablets can then be film coated and polished as is known to those skilled in the art. These tablets comply with applicable U.S.P. and/or F.D.A. requirements/law and are well suited to commercial production and use. Alternatively, but less preferably, the binder can be solvated and used in a wet granulation process.

DEFINITIONS AND CONVENTIONS

The definitions and explanations below are for the terms as used throughout this entire document including both the specification and the claims.

I. DEFINITIONS

Delavirdine refers to 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine.

Delavirdine mesylate refers to 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine mesylate salt.

A "rapidly precipitating drug" is a pharmaceutical compound, or its salt form, which when introduced in water, or simulated physiological fluids at body temperature, begins to dissolve fairly rapidly and then begins to rapidly precipitate out of solution within 60 min to a less soluble form which provides a concentration that is less than therapeutic.

All temperatures are in degrees Centigrade.

Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.

When two or more solids are used in a mixture, they are expressed as weight/weight designated wt/wt or wt.wt.

PVP refers to polyvinylpyrrolidone.

EXAMPLES

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever.

Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.

EXAMPLE 1 Delavirdine Mesylate 200 mg Tablet Formulation

5		200 mg tablet	
	<u>Item</u>	<u>Amount/tablet</u>	<u>%</u>
	(wt.wt)		
	delavirdine mesylate	200.00 mg	30.2
	microcrystalline cellulose N.F.	198.76 mg	30.0
10	coarse powder		
	lactose NF monohydrate spray	71.29 mg	10.7
	process standard		
	hydroxypropyl methylcellulose	75.00 mg	11.3
	2910 U.S.P. 3 cps		
15	croscarmellose sodium N.F.	110.00 mg	16.6
	Type A		
	colloidal silicon dioxide N.F.	1.50 mg	0.23
	magnesium stearate N.F. powder	5.00 mg	0.76
	food grade-V bolted		
20	The above tablets are manufactured by intensely mixing the delavirdine mesylate and the microcrystalline cellulose in a high shear mixer. Then add and mix the hydroxypropyl methylcellulose, croscarmellose, lactose, and screened colloidal silicon dioxide in high shear mixer. Finally add screened magnesium stearate and lubricate in high shear mixer. The resulting mixture is compressed, filmcoated, and		
25	polished as is known to those skilled in the art to give tablets which have about 200 mg of delavirdine mesylate/tablet and comply with U.S.P. and/or F.D.A. requirements.		

CLAIMS

1. A non-sustained release pharmaceutical tablet composition which comprises:
a rapidly precipitating drug in an amount from about 5 to about 60%, microcrystalline
cellulose, and at least one member selected from the group consisting of a binder in
5 an amount of from about 2 to about 25% and a superdisintegrant in an amount from
about 6 to about 40% where the rapidly precipitating drug, microcrystalline cellulose,
binder and superdisintegrant are mixed and compressed into a tablet without heating,
solvent or grinding.
- 10 2. A non-sustained release pharmaceutical tablet composition according to claim 1
where the binder is selected from the group consisting of:
hydroxypropyl methylcellulose,
PVP,
hydroxypropyl cellulose,
15 methylcellulose,
hydroxyethylcellulose,
carbopol,
sodium carboxymethylcellulose.
- 20 3. A non-sustained release pharmaceutical tablet composition according to claim 2
where the binder is hydroxypropyl methylcellulose.
4. A non-sustained release pharmaceutical tablet composition according to claim 2
where the binder is PVP.
- 25 5. A non-sustained release pharmaceutical tablet composition according to claim 2
where the binder is present in an amount as follows for:
hydroxypropyl methylcellulose of from about 5 to about 20%,
PVP from about 2 to about 15%,
30 hydroxypropyl cellulose from about 5 to about 20%,
methylcellulose from about 5 to about 20%,
hydroxyethylcellulose from about 5 to about 20%,
carbopol from about 3 to about 20%,
sodium carboxymethylcellulose from about 3 to about 20%.

35

6. A non-sustained release pharmaceutical tablet composition according to claim 1 where the superdisintegrant is croscarmellose sodium, sodium starch glycolate, L-hydroxypropyl cellulose.

5 7. A non-sustained release pharmaceutical tablet composition according to claim 1 where the superdisintegrant is present in an amount of from about 6 to about 35%.

8. A non-sustained release pharmaceutical tablet composition according to claim 7 where the superdisintegrant is present in an amount of from about 10 to about
10 30%.

9. A non-sustained release pharmaceutical tablet composition according to claim 1 which contains microcrystalline cellulose in an amount up to about 50%.

15 10. A non-sustained release pharmaceutical tablet composition according to claim 1 where the microcrystalline cellulose is selected from the group consisting of
microcrystalline cellulose coarse powder,
microcrystalline cellulose medium powder and
microcrystalline cellulose 200.

20 11. A non-sustained release pharmaceutical tablet composition according to claim 9 where the microcrystalline cellulose is microcrystalline cellulose N.F. coarse powder.

12. A non-sustained release pharmaceutical tablet composition according to claim 1
25 where the microcrystalline cellulose is present in an amount of from about 10 to about 40%.

13. A non-sustained release pharmaceutical tablet composition according to claim 1 which contains lactose in an amount up to about 80%.

30 14. A non-sustained release pharmaceutical tablet composition according to claim 13 where the lactose is selected from the group consisting of lactose monohydrate spray process standard, lactose monohydrate, lactose anhydrous, lactose dihydrate, DMV lactose.

35

15. A non-sustained release pharmaceutical tablet composition according to claim 13 where the lactose is N.F. monohydrate spray process standard lactose.
16. A non-sustained release pharmaceutical tablet composition according to claim 12 where the lactose is present in an amount of from about 5 to about 20%.
17. A non-sustained release pharmaceutical tablet composition according to claim 1 which contains a flow agent in an amount up to 5%.
18. A non-sustained release pharmaceutical tablet composition according to claim 17 where the flow agent is selected from the group consisting of colloidal silicon dioxide and talc.
19. A non-sustained release pharmaceutical tablet composition according to claim 17 where the flow agent is colloidal silicon dioxide N.F.
20. A non-sustained release pharmaceutical tablet composition according to claim 1 where the flow agent is present in an amount from 0.25 to about 2%.
21. A non-sustained release pharmaceutical tablet composition according to claim 1 which contains a lubricant in an amount up to 5%.
22. A non-sustained release pharmaceutical tablet composition according to claim 21 where the lubricant is selected from the group consisting of magnesium stearate and stearic acid.
23. A non-sustained release pharmaceutical tablet composition according to claim 21 where the lubricant is magnesium stearate.
24. A non-sustained release pharmaceutical tablet composition according to claim 1 where the lubricant is present in an amount of 0.25 to about 2%.
25. A non-sustained release pharmaceutical tablet composition according to claim 1 where the rapidly precipitating drug is selected from the group consisting of delavirdine mesylate, phenytoin, furosemide, pseudoephedrine, clindamycin hydrochloride, cloridine hydrochloride, diphenhydramine hydrochloride, fluphenazine

hydrochloride, griseofulvin, hydromorphone hydrochloride, naloxone hydrochloride, oxytetracycline hydrochloride, phenylephrine hydrochloride, pheniramine maleate, tetracycline hydrochloride, verapamil hydrochloride, propoxyphene hydrochloride, propoxyphene napsylate, hydrocodone bitartrate, acyclovir sodium, albuterol sulfate, 5 ampicillin sodium, benztropine mesylate, benzphetamine hydrochloride, bupivacaine hydrochloride, bupropin hydrochloride, chlorphenamine maleate, chlorpromazine hydrochloride.

26. A non-sustained release pharmaceutical tablet composition according to claim 1 10 where the rapidly precipitating drug is present in an amount of from about 10 to about 40%.

27. A non-sustained release pharmaceutical tablet composition according to claim 25 15 where the rapidly dissolving drug is delavirdine mesylate.

28. A non-sustained release pharmaceutical tablet composition according to claim 27 where the delavirdine mesylate is present in an amount of from about 50 to about 300 mg/tablet.

29. A non-sustained release pharmaceutical tablet composition according to claim 27 20 where the delavirdine mesylate is present in an amount of about 200 or about 300 mg/tablet.

30. A non-sustained release pharmaceutical tablet composition according to claim 1 25 which contains both a binder and superdisintegrant.

31. A non-sustained release pharmaceutical tablet composition which is:

		<u>Amount (from about to about)</u>
	<u>Item</u>	<u>%</u>
30	delavirdine mesylate	10-40
	hydroxypropyl methylcellulose	5-20
	croscarmellose sodium	6-35
	microcrystalline cellulose	10-50
	lactose	0-15
35	colloidal silicon dioxide	0-5
	magnesium stearate	0-5

where the delavirdine mesylate, microcrystalline cellulose, hydroxypropyl methylcellulose and croscarmellose sodium are mixed and compressed into a tablet without heating, solvent or grinding.

5

32. A non-sustained release pharmaceutical tablet composition according to claim 31 which is:

	<u>Item</u>	<u>Amount (from about to about)</u>
		<u>%.</u>
10	delavirdine mesylate	30.2
	hydroxypropyl methylcellulose	11.3
	2910 U.S.P. 3 cps	
	croscarmellose sodium N.F.	16.6
	Type A	
15	microcrystalline Cellulose N.F.	30.0
	coarse powder	
	lactose NF monohydrate spray	10.7
	process standard	
	colloidal silicon dioxide N.F.	0.23
20	magnesium stearate N.F. powder	0.76
	food grade-V bolted	

DELAVIDINE TABLET FORMULATIONABSTRACT

Disclosed is a non-sustained release pharmaceutical tablet composition which
5 comprises a rapidly precipitating drug in an amount from about 5 to about 60% and at
least one member selected from the group consisting of a binder in an amount of from
about 2 to about 25% and a superdisintegrant in an amount from about 6 to about
40% where the rapidly precipitating drug, "binder" and superdisintegrant are mixed
and compressed into a tablet without heating, solvent or grinding.

10

DECLARATION (37 CFR §1.63) AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **Delavirdine Tablet Formulation**, Docket No. 6107. N CN1, the specification of which

☐ is attached hereto.

☒ was filed on June 7, 1999, as Application Serial No. 09/327,135, and was amended on .

☐ was filed on, as PCT International Application No., and was amended under PCT Article 19 on , if applicable.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 CFR §1.56(a).

I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date (Day/Month/Year)
---------------------------	---------------------------------

60/088,960	June 11, 1998
------------	---------------

I hereby claim foreign priority benefits under 35 USC §119(a)-(d), or §365(b), of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed:

Application Serial No.	Country	Filing Date (Day/Month/Year)	Priority Claimed (Yes/No)
---------------------------	---------	---------------------------------	------------------------------

009060"4929960

I hereby claim the benefit under 35 USC §120, of any United States application(s) or PCT International Application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of 35 USC §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>Application</u> <u>Serial No.</u>	<u>Filing Date</u>	<u>Status (Patented,</u> <u>Pending, Abandoned)</u>
---	--------------------	--

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint James D. Darnley, Jr. (Registration No. 33,673), Bruce Stein (Registration No. 27,231), Thomas A. Wootton (Registration No. 35,004), Lucy X. Yang (Registration No. 40,259), Andrew M. Solomon (Registration No. 32,175), Edward F. Rehberg (Registration No. 34,703), Ellen Park (Registration No. 34,055, and Bruce A. Pokras (Registration No. 32,748), all registered to practice before the Patent and Trademark Office as my attorneys or agents with full power of substitution and revocation to prosecute this application and all divisions and continuations thereof and to transact all business in the Patent and Trademark Office connected therewith and request that all correspondence and telephone communications be directed to the following person(s) at the mailing address and telephone number hereafter given:

Name	:	Bruce Stein, Attorney
Registration No.	:	27,231
Address	:	Global Intellectual Property Pharmacia & Upjohn Company Kalamazoo, Michigan 49001
Telephone No.	:	(616) 833-1127 or (616) 833-9500
Telefax No.	:	(616) 833-8897 or (616) 833-2316

009060-4329960

Inventor's Signature Alice C Martino Date Jan 6, 2000

Full name of sole or first inventor: Alice C. Martino
 Residence: Kalamazoo, Michigan 49009 Citizenship: USA
 Post Office Address: 6232 Far Hills Way, Kalamazoo, Michigan 49009

Inventor's Signature [Signature] Date 21 OCT 99

Full name of second joint inventor: Ashley H. Bates
 Residence: Sorrento, WA. Australia 6020 Citizenship: UK
 Post Office Address: 12 Hakea Place, Sorrento, WA. Australia 6020

Inventor's Signature Walter Morozowich Date Jan. 6, 2000

Full name of third joint inventor: Walter Morozowich
 Residence: Kalamazoo, Michigan 49002 Citizenship: USA
 Post Office Address: 5330 Chickadee, Kalamazoo, Michigan 49002

Inventor's Signature E. John Lee Date JAN 6, 2000

Full name of fourth joint inventor: E. John Lee
 Residence: Kalamazoo, Michigan 49009 Citizenship: USA
 Post Office Address: 5250 Colony Woods, Kalamazoo, Michigan 49009

005060-49E35960